When CGT Supply Chains Break Down: 5 Operational Gaps That Put Patient Outcomes At Risk

A single delayed shipment in cell and gene therapy isn't a logistics inconvenience. It's a missed treatment window for a patient who may have no other options. Yet most CGT organizations don't recognize the operational gaps quietly eroding their supply chains until something has already gone wrong. The warning signs appear subtly at first: clinical staff pulled into shipment coordination, condition data that arrives too late to act on, and visibility tools that only confirm failures rather than prevent them.

This article identifies five critical gaps that separate high-performing CGT supply chains from those operating at risk. Understanding these vulnerabilities is the first step toward building a supply chain where logistics support patient outcomes rather than threaten them. If any of these gaps sound familiar, it's time to engage a logistics partner with deep expertise in advanced therapies.